OPTN OptiNose

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024.

Company to Host Conference Call

Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 7, 2024.

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at . To participate via telephone, please register in advance at . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit  or follow us on and .

Optinose Investor Contact

Jonathan Neely



267.521.0531



EN
29/02/2024

Underlying

OPTNOptiNose

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Inves...

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay...

May 17, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Reports First Quarter 2024 Financial Results and Recent Opera...

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2...

May 14, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Reporting Date for First Quarter 2024 Financial Res...

Optinose Announces Reporting Date for First Quarter 2024 Financial Results Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss f...

May 10, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces $55 Million Registered Direct Offering

Optinose Announces $55 Million Registered Direct Offering Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024     YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into agreements for the sale of a...

May 9, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Provides Corporate Update on XHANCE Launch and Outlook and An...

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch